Denali Therapeutics (NASDAQ:DNLI) Given New $24.00 Price Target at JPMorgan Chase & Co.
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its target price decreased by stock analysts at JPMorgan Chase & Co. from $28.00 to $24.00 in a research report issued on Tuesday,Benzinga ...
marketinference23h
Denali Therapeutics Misses Primary Endpoint in ALS Trial
For the primary analysis, a total of 186 participants who received DNL343 treatment were compared to 139 participants who ...